Sign In
Buy OPY
$106.64
-4.06 (-3.67%)
At Close: Jul 31, 2026
Oppenheimer's Colin Rusch on why he's neutral on Tesla
09:01am, Friday, 14'th Feb 2025
Colin Rusch, Oppenheimer senior research analyst, joins 'Squawk Box' to discuss Tesla's stock performance, the company's autonomous ambitions, impact of Elon Musk's role in Washington, and more.
Achieve Life Sciences to Present at the Oppenheimer Healthcare Life Sciences Conference
08:30am, Tuesday, 11'th Feb 2025
SEATTLE and VANCOUVER, British Columbia, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development
Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
04:45pm, Monday, 10'th Feb 2025
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize c
DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
04:15pm, Monday, 10'th Feb 2025
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced toda
Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference
08:00am, Friday, 07'th Feb 2025
MALVERN, Pa., Feb. 07, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies
Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
04:05pm, Thursday, 06'th Feb 2025
CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to
Oppenheimer: Solid Topline Performance And Multiple, But Comp Expense Caps Profit Growth
08:51am, Thursday, 06'th Feb 2025
Profits are scaling in the advisory and capital markets business thanks to a standout performance on a relatively immature and high growth platform. Latent earnings are considerable for capital market
Y-mAbs to Present at the Oppenheimer 35ᵗʰ Annual Life Sciences Conference
07:30am, Thursday, 06'th Feb 2025
NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and co
Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
07:00am, Thursday, 06'th Feb 2025
JUPITER, Fla.--(BUSINESS WIRE)--Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference.
Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
04:05pm, Wednesday, 05'th Feb 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biolog
Adverum Biotechnologies to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
04:05pm, Wednesday, 05'th Feb 2025
REDWOOD CITY, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly p
Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
04:05pm, Wednesday, 05'th Feb 2025
FOSTER CITY, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio
scPharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
04:01pm, Wednesday, 05'th Feb 2025
BURLINGTON, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through pat
Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
08:05am, Wednesday, 05'th Feb 2025
FLORHAM PARK, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercializ
Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
08:00am, Wednesday, 05'th Feb 2025
SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral the
